Nurix Therapeutics reports Q1 EPS (67c), consensus (76c)

Reports Q1 revenue $18.45M, consensus $13.03M. “Nurix had a strong first quarter marked by important collaboration and regulatory achievements and key additions to our leadership team and Board,” said Arthur Sands, president and chief executive officer of Nurix. “Nurix remains on track to initiate pivotal trials of bexobrutideg, our oral, brain-penetrant, BTK degrader for the treatment of patients with chronic lymphocytic leukemia in 2025. In addition, Nurix continues to make significant progress with our pipeline of degrader-based drugs for the treatment of autoimmune disease and inflammation. Most recently we announced that Sanofi exercised its option to exclusively license an undisclosed Nurix program targeting a previously undruggable transcription factor that is a central regulator of the inflammation response and is distinct from the previously disclosed STAT6 degrader program.”